Cellectar Biosciences, Inc. (CLRBW)

0.01 6.04
Prev Close 0.09
Open 0.10
Day Low/High 0.10 / 0.10
52 Wk Low/High 0.04 / 0.79
Volume 200.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Covers composition of matter and method of use for proprietary PDCs™ in combination with anti-cancer agents

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Conference call to be held tomorrow at 8:30 a.m. Eastern time

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit